Unnatural Products Announces Research Discovery Collaboration with BridgeBio Pharma to Target Rare Diseases with Potential Oncology Applications
Retrieved on:
Tuesday, October 12, 2021
By leveraging UNPs technology, which takes macrocyclic tool compounds and turns them into drugs, UNP and BridgeBio will generate drug-like macrocycles with the hopes of creating the capabilities to hit intracellular targets associated with rare fibrotic diseases and potential oncology applications.
Key Points:
- By leveraging UNPs technology, which takes macrocyclic tool compounds and turns them into drugs, UNP and BridgeBio will generate drug-like macrocycles with the hopes of creating the capabilities to hit intracellular targets associated with rare fibrotic diseases and potential oncology applications.
- The companys AI-enhanced technology platform enables new drugs by engineering passively permeable, macrocyclic peptides that access traditionally undruggable targets.
- UNP and BridgeBio are working to turn initial chemical series from exciting academic tool compounds into promising therapeutics.
- We are pleased to be partnering with Unnatural Products to try and address diseases that have thus far have been challenging to treat.